Search

Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during The American Society of Hematology (ASH) annual meeting, December 9-12 in San Diego, CA.

… Tuesday, December 5, 2023 Physicians and scientists from Memorial Sloan Kettering Cancer Center (MSK) will join oncology experts and members of the global cancer research community to present the latest advances in cancer during The American Society of Hematology (ASH) annual meeting, December 9-12 in

For those living with advanced cancer, quality of life means pursuing what matters most to each person — whether that’s making art, running marathons, caring for others, or spending more time with family.

… Friday, June 6, 2025 Cancer that spreads from an initial tumor to other parts of the body — known as metastasis — is a daunting diagnosis that brings with it a great deal of fear and uncertainty. While metastatic cancer remains challenging, significant advances in diagnosis and treatment are making it

Overcoming resistance to drug treatment for lung cancer is a critical challenge.

… Thursday, November 29, 2018 Summary Investigators are looking for ways to overcome resistance to drugs that target lung cancer. Lung cancer was one of the first cancers that could be targeted by drugs aimed at specific mutations in tumors. Advances in genomic medicine and the molecular analysis of tumors

Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years.

… Wednesday, September 27, 2006 Results from the largest study of men with prostate cancer treated with high-dose, intensity modulated radiation therapy (IMRT) show that the majority of patients remain alive with no evidence of disease after an average follow-up period of eight years. The 561 prostate

Memorial Sloan Kettering attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice.

… Wednesday, November 25, 2020 VIDEO | 03:09 2020 MSK Nurses Magnet Recognition Video Details On November 23, 2020, Memorial Sloan Kettering (MSK) attained Magnet recognition for the second time, a testament to our continued dedication to high-quality nursing practice. The American Nurses Credentialing

MSK’s Convocation and the Gerstner Sloan Kettering Graduate School of Biomedical Sciences Commencement celebrate the achievements of young scientists.

… Wednesday, June 10, 2015 Ruth Anne Franklin (left), Ming Li, Myoungjoo Kim Graduates Ruth Anne Franklin (left) and Myoungjoo Kim with their mentor, immunologist Ming Li 2015 graduates Graduates of GSK and a joint program between Weill Cornell Medical College and the Sloan Kettering Institute with their

Get to know Abby Hawk, who got a tattoo of Memorial Sloan Kettering after being treated there for neuroblastoma.

… Friday, September 10, 2021 VIDEO | 00:04 Abby Leaves Her Mark Abby's tattoo shows the latitude and longitude of Memorial Sloan Kettering Cancer Center and the quote "The comeback is always stronger than the setback." Video Details It was a bold request. A high school senior living outside Toledo named

A lifelong smoker overcomes discomfort over what a lung cancer imaging test might reveal. She hopes her experience helps reduce the stigma for others who smoke.

… Thursday, September 19, 2024 Marylou Capes-Platt knew she was at an especially high risk for lung cancer . She had been a heavy smoker for 45 years, starting in her teens and continuing through a decades-long career in the music industry and as a writer and editor. She finally quit in 2007. But the threat

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

… Tuesday, April 30, 2013 Summary Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide. Targeted therapies hold promise for the treatment of many types of cancer. But a common predicament is that in many patients

The initiative lays the groundwork for speedier cancer drug approvals in both the United States and China.

… Tuesday, December 22, 2020 Summary The 3rd annual MSK-CTONG Symposium virtually brought together leading medical experts, including academic physicians, scientific leadership from pharmaceutical and biotechnology industries, as well as government regulators, to discuss US-China and international clinical